Drug industry payments to eye docs boosted Medicare spending on pricier treatments; What will Novo’s VC do with its influx of cash?

Taking stock of the drug industry, from the lab to the medicine chest

September 28, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Drug industry payments to eye docs boosted Medicare spending on pricier treatments Doctors who took payments from drugmakers were less likely to prescribe a cheap drug to treat an eye disease that causes blindness in seniors. By Ed Silverman STAT+ | What will Novo's VC do with its influx of cash? Don't expect obesity investments The investment group has been tasked with taking the influx of Ozempic and Wegovy revenues and growing them. By Allison DeAngelis A STAT analysis shows how top drug companies are starting to take action on climate In a new report, STAT ranks drug companies on efforts to battle climate change, including reducing greenhouse gas emissions. By Betsy Ladyzhets Drew Angerer/Getty Images Did the government get a bad deal on the Covid-19 boosters? After Pfizer and Moderna hiked the prices of their Covid vaccines, the government will pay nearly three times more per dose. By Rachel Cohrs

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser